<DOC>
	<DOCNO>NCT01609231</DOCNO>
	<brief_summary>The purpose adaptive trial compare progression-free survival participant metastatic rectal carcinoma treat dalotuzumab + irinotecan therapy relative participant treat cetuximab + irinotecan .</brief_summary>
	<brief_title>A Trial Dalotuzumab Combination With Irinotecan Versus Cetuximab Irinotecan Participants With Metastatic Rectal Cancers ( mRC ) ( MK-0646-025 )</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Metastatic colorectal cancer primary tumor originate rectum Available archival ( recent remote ) tumor , newly obtain formalinfixed tissue available analysis biomarker study At least one measurable lesion great equal 10 mm Disease progress treatment irinotecan oxaliplatin contain regimen progress within 3 month complete last line therapy Performance status 01 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Known diabetic poorly control Chemotherapy biological therapy within 2 week prior initial dose study , whose toxicity agent administer 2 week earlier resolve least grade 1 baseline , within 3 week prior surgery Radiotherapy within 2 week prior initial dose study , unless radiotherapy management pain Currently participate participate study investigational compound device within 30 day 5 halflives investigational agent , whichever longer , initial dosing study Could complete previous course irinotecan due intolerable toxicity , discontinuation due fatigue follow prolonged administration ( &gt; 4 month exposure ) Prior exposure insulinlike growth factor 1 receptor ( IGF1R ) inhibitor epidermal growth factor receptor ( EGFR ) inhibitor Known Central Nervous System ( CNS ) metastases and/or carcinomatous meningitis Primary CNS tumor History prior malignancy exception cervical intraepithelial neoplasia ; basal cell carcinoma skin ; adequately treat localized prostate carcinoma ; potentially curative therapy evidence disease 5 year , deem low risk recurrence treat physician . Human Immunodeficiency Virus ( HIV ) positive Active Hepatitis B C receive antiviral treatment regimens Symptomatic ascites pleural effusion Concurrently use growth hormone ( GH ) , growth hormone inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>